Cargando…

Elevation of plasma phosphorylated tau181 during neurological illnesses affecting consciousness and kidney dysfunction

INTRODUCTION: Phosphorylated tau (p‐tau)181 has become a promising blood‐based Alzheimer's disease (AD) biomarker. We studied the agreement of plasma p‐tau181 and cerebrospinal fluid (CSF) markers in patients with alteration of consciousness (AOC). METHODS: Plasma and CSF were simultaneously co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thanapornsangsuth, Poosanu, Ongphichetmetha, Tatchaporn, Luechaipanit, Watayuth, Hemachudha, Pasin, Hemachudha, Thiravat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Fluid Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523798/ https://www.ncbi.nlm.nih.gov/pubmed/36204656 http://dx.doi.org/10.1002/dad2.12358

Ejemplares similares

Neurofilament light chain for classifying the aetiology of alteration of consciousness
por: Ongphichetmetha, Tatchaporn, et al.
Publicado: (2023)

Neurofilament light is associated with clinical outcome and hemorrhagic transformation in moderate to severe ischemic stroke
por: Rattanawong, Wanakorn, et al.
Publicado: (2023)

COVID-19 related acute necrotizing encephalopathy with extremely high interleukin-6 and RANBP2 mutation in a patient with recently immunized inactivated virus vaccine and no pulmonary involvement
por: Pongpitakmetha, Thanakit, et al.
Publicado: (2022)

Higher baseline levels of CSF inflammation increase risk of incident mild cognitive impairment and Alzheimer's disease dementia
por: Contreras, Joey A., et al.
Publicado: (2022)

Plasma biomarkers predict cognitive trajectories in an ethnoracially and clinically diverse cohort: Mediation with hippocampal volume
por: Sapkota, Shraddha, et al.
Publicado: (2022)

Hepatic and renal function impact concentrations of plasma biomarkers of neuropathology
por: Berry, Kacey, et al.
Publicado: (2022)

A case of successive development of possible acute necrotizing encephalopathy after COVID-19 pneumonia
por: Hemachudha, Pasin, et al.
Publicado: (2022)

CSF metabolites associate with CSF tau and improve prediction of Alzheimer's disease status
por: Dong, Ruocheng, et al.
Publicado: (2021)

The relationship between cerebrospinal fluid tau markers, hippocampal volume, and delayed primacy performance in cognitively intact elderly individuals
por: Bruno, Davide, et al.
Publicado: (2015)

P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
por: Campbell, Michelle R., et al.
Publicado: (2021)

Higher cerebrospinal fluid tau is associated with history of traumatic brain injury and reduced processing speed in Vietnam‐era veterans: A Department of Defense Alzheimer's Disease Neuroimaging Initiative (DOD‐ADNI) study
por: Clark, Alexandra L., et al.
Publicado: (2021)

IP-10 and complement activation as friend or foe in COVID-19
por: Bunprakob, Saowalak, et al.
Publicado: (2022)

Encephalitis in Thailand: A Neglected Disease Increasingly Caused by Enterovirus
por: Hemachudha, Pasin, et al.
Publicado: (2021)

Can agrin cerebrospinal fluid concentration be used as an early biomarker for Alzheimer's disease?
por: Del Campo Milan, Marta, et al.
Publicado: (2015)

Clearance of interstitial fluid (ISF) and CSF (CLIC) group—part of Vascular Professional Interest Area (PIA): Cerebrovascular disease and the failure of elimination of Amyloid‐β from the brain and retina with age and Alzheimer's disease‐Opportunities for Therapy
por: Carare, Roxana O., et al.
Publicado: (2020)

Untargeted metabolomics reveal dysregulations in sugar, methionine, and tyrosine pathways in the prodromal state of AD
por: Hajjar, Ihab, et al.
Publicado: (2020)

The effect of lumbar puncture on the neurodegeneration biomarker neurofilament light in macaque monkeys
por: Boehnke, Susan E., et al.
Publicado: (2020)

Cerebrospinal fluid irisin correlates with amyloid‐β, BDNF, and cognition in Alzheimer's disease
por: Lourenco, Mychael V., et al.
Publicado: (2020)

An automated clinical mass spectrometric method for identification and quantification of variant and wild‐type amyloid‐β 1‐40 and 1‐42 peptides in CSF
por: DeMarco, Mari L., et al.
Publicado: (2020)

Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays
por: Keshavan, Ashvini, et al.
Publicado: (2020)

Depressive symptoms and CSF Alzheimer's disease biomarkers in relation to clinical symptom onset of mild cognitive impairment
por: Chan, Carol K., et al.
Publicado: (2020)

Deciphering the factors that influence participation in studies requiring serial lumbar punctures
por: Day, Gregory S., et al.
Publicado: (2020)

Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease
por: Dhiman, Kunal, et al.
Publicado: (2020)

A high cerebrospinal fluid soluble TREM2 level is associated with slow clinical progression of Alzheimer's disease
por: Edwin, Trine Holt, et al.
Publicado: (2020)

Periodontal dysbiosis associates with reduced CSF Aβ42 in cognitively normal elderly
por: Kamer, Angela R., et al.
Publicado: (2021)

Pre‐analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF
por: Hansson, Oskar, et al.
Publicado: (2020)

Association of cognitive impairment severity with potentially avoidable readmissions: A retrospective cohort study of 8897 older patients
por: Mitsutake, Seigo, et al.
Publicado: (2021)

Sex differences in CSF biomarkers for neurodegeneration and blood‐brain barrier integrity
por: Skillbäck, Tobias, et al.
Publicado: (2021)

Effects of age, amyloid, sex, and APOE ε4 on the CSF proteome in normal cognition
por: Wesenhagen, Kirsten E.J., et al.
Publicado: (2022)

Diagnostic and prognostic performance of CSF α‐synuclein in prion disease in the context of rapidly progressive dementia
por: Mastrangelo, Andrea, et al.
Publicado: (2021)

Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
por: Nilsson, Johanna, et al.
Publicado: (2021)

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
por: Willemse, Eline A. J., et al.
Publicado: (2021)

Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays
por: Keshavan, Ashvini, et al.
Publicado: (2021)

Measurement batch differences and between‐batch conversion of Alzheimer's disease cerebrospinal fluid biomarker values
por: Ma, Yue, et al.
Publicado: (2021)

Interaction of CSF α‐synuclein and amyloid beta in cognition and cortical atrophy
por: Lee, Young‐gun, et al.
Publicado: (2021)

A study of the longitudinal changes in multiple cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers on converter and non‐converter Alzheimer's disease subjects with consideration for their amyloid beta status
por: Morar, Ulyana, et al.
Publicado: (2022)

Lack of Transmission of Zika Virus Infection to Breastfed Infant
por: Hemachudha, Pasin, et al.
Publicado: (2019)

Objective subtle cognitive decline and plasma phosphorylated tau181: Early markers of Alzheimer's disease‐related declines
por: Thomas, Kelsey R., et al.
Publicado: (2021)

Pneumomediastinum as initial presentation of paralytic rabies: A case report
por: Kietdumrongwong, Pongtorn, et al.
Publicado: (2005)

Continued Failure of Rabies Elimination—Consideration of Challenges in Applying the One Health Approach
por: Ghai, Siriporn, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t9km9ohau621drsavdrfougd5j